Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer

Hyejin Choi, Jiehui Deng, Shuai Li, Tarik Silk, Lauren Dong, Elliott J. Brea, Sean Houghton, David Redmond, Hong Zhong, Jonathan Boiarsky, Esra Akbay, Paul D. Smith, Taha Merghoub, Kwok Kin Wong, Jedd D. Wolchok

Research output: Contribution to journalArticle

Abstract

KRAS mutant non-small-cell lung cancer (NSCLC) remains refractory to targeted therapeutics. Choi et al. show that pulsatile, rather than continuous, treatment with MEK inhibitors can maintain T cell activity better and prolong survival in mice with Kras mutant cancer. This effect is further enhanced when combined with CTLA-4 blockade.

Original languageEnglish (US)
Pages (from-to)806-819.e5
JournalCell Reports
Volume27
Issue number3
DOIs
StatePublished - Apr 16 2019

Fingerprint

T-cells
Mitogen-Activated Protein Kinase Kinases
Non-Small Cell Lung Carcinoma
Refractory materials
Tumors
Immunity
Lung Neoplasms
Cells
T-Lymphocytes
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Choi, H., Deng, J., Li, S., Silk, T., Dong, L., Brea, E. J., ... Wolchok, J. D. (2019). Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer. Cell Reports, 27(3), 806-819.e5. https://doi.org/10.1016/j.celrep.2019.03.066

Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer. / Choi, Hyejin; Deng, Jiehui; Li, Shuai; Silk, Tarik; Dong, Lauren; Brea, Elliott J.; Houghton, Sean; Redmond, David; Zhong, Hong; Boiarsky, Jonathan; Akbay, Esra; Smith, Paul D.; Merghoub, Taha; Wong, Kwok Kin; Wolchok, Jedd D.

In: Cell Reports, Vol. 27, No. 3, 16.04.2019, p. 806-819.e5.

Research output: Contribution to journalArticle

Choi, H, Deng, J, Li, S, Silk, T, Dong, L, Brea, EJ, Houghton, S, Redmond, D, Zhong, H, Boiarsky, J, Akbay, E, Smith, PD, Merghoub, T, Wong, KK & Wolchok, JD 2019, 'Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer', Cell Reports, vol. 27, no. 3, pp. 806-819.e5. https://doi.org/10.1016/j.celrep.2019.03.066
Choi, Hyejin ; Deng, Jiehui ; Li, Shuai ; Silk, Tarik ; Dong, Lauren ; Brea, Elliott J. ; Houghton, Sean ; Redmond, David ; Zhong, Hong ; Boiarsky, Jonathan ; Akbay, Esra ; Smith, Paul D. ; Merghoub, Taha ; Wong, Kwok Kin ; Wolchok, Jedd D. / Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer. In: Cell Reports. 2019 ; Vol. 27, No. 3. pp. 806-819.e5.
@article{ce2c28a6d64c4ebfbb325b3484ea93a0,
title = "Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer",
abstract = "KRAS mutant non-small-cell lung cancer (NSCLC) remains refractory to targeted therapeutics. Choi et al. show that pulsatile, rather than continuous, treatment with MEK inhibitors can maintain T cell activity better and prolong survival in mice with Kras mutant cancer. This effect is further enhanced when combined with CTLA-4 blockade.",
author = "Hyejin Choi and Jiehui Deng and Shuai Li and Tarik Silk and Lauren Dong and Brea, {Elliott J.} and Sean Houghton and David Redmond and Hong Zhong and Jonathan Boiarsky and Esra Akbay and Smith, {Paul D.} and Taha Merghoub and Wong, {Kwok Kin} and Wolchok, {Jedd D.}",
year = "2019",
month = "4",
day = "16",
doi = "10.1016/j.celrep.2019.03.066",
language = "English (US)",
volume = "27",
pages = "806--819.e5",
journal = "Cell Reports",
issn = "2211-1247",
publisher = "Cell Press",
number = "3",

}

TY - JOUR

T1 - Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer

AU - Choi, Hyejin

AU - Deng, Jiehui

AU - Li, Shuai

AU - Silk, Tarik

AU - Dong, Lauren

AU - Brea, Elliott J.

AU - Houghton, Sean

AU - Redmond, David

AU - Zhong, Hong

AU - Boiarsky, Jonathan

AU - Akbay, Esra

AU - Smith, Paul D.

AU - Merghoub, Taha

AU - Wong, Kwok Kin

AU - Wolchok, Jedd D.

PY - 2019/4/16

Y1 - 2019/4/16

N2 - KRAS mutant non-small-cell lung cancer (NSCLC) remains refractory to targeted therapeutics. Choi et al. show that pulsatile, rather than continuous, treatment with MEK inhibitors can maintain T cell activity better and prolong survival in mice with Kras mutant cancer. This effect is further enhanced when combined with CTLA-4 blockade.

AB - KRAS mutant non-small-cell lung cancer (NSCLC) remains refractory to targeted therapeutics. Choi et al. show that pulsatile, rather than continuous, treatment with MEK inhibitors can maintain T cell activity better and prolong survival in mice with Kras mutant cancer. This effect is further enhanced when combined with CTLA-4 blockade.

UR - http://www.scopus.com/inward/record.url?scp=85064175042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064175042&partnerID=8YFLogxK

U2 - 10.1016/j.celrep.2019.03.066

DO - 10.1016/j.celrep.2019.03.066

M3 - Article

VL - 27

SP - 806-819.e5

JO - Cell Reports

JF - Cell Reports

SN - 2211-1247

IS - 3

ER -